Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
BMC Res Notes ; 12(1): 495, 2019 Aug 09.
Artículo en Inglés | MEDLINE | ID: mdl-31399144

RESUMEN

OBJECTIVE: Although infant mortality because of birth defect has increased in both developed and developing countries, had not got attention like other health issues at national, regional, or local levels. Documenting the risk factors that influence the occurrence of birth defects and its seasonality will help to inform the community and to develop preventive strategies for the country. RESULTS: Factors associated with higher likelihood of a major structural birth defects included maternal age; neonates born from women living in urban; and in Dega; history of fever during pregnancy; intake of herbal medicine; and drinking alcohol. Counselling for pregnancy preparation and folic acid supplementation was found protective for the likelihood of birth defect.


Asunto(s)
Labio Leporino/epidemiología , Fisura del Paladar/epidemiología , Anomalías Congénitas/epidemiología , Anomalías Musculoesqueléticas/epidemiología , Defectos del Tubo Neural/epidemiología , Adulto , Consumo de Bebidas Alcohólicas/efectos adversos , Estudios de Casos y Controles , Labio Leporino/etiología , Labio Leporino/prevención & control , Fisura del Paladar/etiología , Fisura del Paladar/prevención & control , Anomalías Congénitas/etiología , Anomalías Congénitas/prevención & control , Países en Desarrollo , Suplementos Dietéticos , Etiopía/epidemiología , Femenino , Fiebre/complicaciones , Ácido Fólico/administración & dosificación , Humanos , Lactante , Recién Nacido , Masculino , Edad Materna , Anomalías Musculoesqueléticas/etiología , Anomalías Musculoesqueléticas/prevención & control , Defectos del Tubo Neural/etiología , Defectos del Tubo Neural/prevención & control , Parto , Embarazo , Derivación y Consulta , Factores de Riesgo , Estaciones del Año , Población Urbana
2.
Toxicol Appl Pharmacol ; 363: 111-121, 2019 01 15.
Artículo en Inglés | MEDLINE | ID: mdl-30468815

RESUMEN

Epidemiological studies suggest tobacco consumption as a probable environmental factor for a variety of congenital anomalies, including low bone mass and increased fracture risk. Despite intensive public health initiatives to publicize the detrimental effects of tobacco use during pregnancy, approximately 10-20% of women in the United States still consume tobacco during pregnancy, some opting for so-called harm-reduction tobacco. These include Snus, a type of orally-consumed yet spit-free chewing tobacco, which is purported to expose users to fewer harmful chemicals. Concerns remain from a developmental health perspective since Snus has not reduced overall health risk to consumers and virtually nothing is known about whether skeletal problems from intrauterine exposure arise in the embryo. Utilizing a newly developed video-based calcification assay we determined that extracts from Snus tobacco hindered calcification of osteoblasts derived from pluripotent stem cells early on in their differentiation. Nicotine, a major component of tobacco products, had no measurable effect in the tested concentration range. However, through the extraction of video data, we determined that the tobacco-specific nitrosamine N'-nitrosonornicotine caused a reduction in calcification with similar kinetics as the complete Snus extract. From measurements of actual nitrosamine concentrations in Snus tobacco extract we furthermore conclude that N'-nitrosonornicotine has the potential to be a major trigger of developmental osteotoxicity caused by Snus tobacco.


Asunto(s)
Calcificación Fisiológica/efectos de los fármacos , Células Madre Embrionarias Humanas/efectos de los fármacos , Nitrosaminas/toxicidad , Osteogénesis/efectos de los fármacos , Tabaco sin Humo/toxicidad , Línea Celular , Células Madre Embrionarias Humanas/fisiología , Humanos , Microscopía Intravital , Anomalías Musculoesqueléticas/inducido químicamente , Anomalías Musculoesqueléticas/prevención & control , Osteoblastos/efectos de los fármacos , Osteoblastos/fisiología , Extractos Vegetales/química , Extractos Vegetales/toxicidad , Imagen de Lapso de Tiempo , Nicotiana/química , Nicotiana/toxicidad , Estados Unidos
3.
Ortop Traumatol Rehabil ; 15(2): 159-68, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23652536

RESUMEN

BACKGROUND: A restriction in ankle dorsiflexion is a common complication of ankle fractures. This kind of dysfunction, if severe, can significantly influence gait. A restriction in ankle dorsiflexion (forward movement of the shin relative to the foot) can cause, among others, hyperextension of the knee during the stance phase. The length of leading leg step is shortened and alternant walk downstairs is very difficult. The aim of this study was to examine the correlation between the range of dorsiflexion in the ankle joint and the range of extension (hyperextension) in the knee joint. MATERIAL AND METHODS: The study enrolled 17 patients after ankle joint fractures treated conservatively or surgically. The extension ranges of motion in the ankle and knee joints were assessed by goniometry to compare these values in injured vs. healthy limbs. Non-parametric methods (the Wilcoxon signed-rank test) were used for the analysis. RESULTS: The results showed limitation in ankle dorsiflexion in the fractured limb, which amounted to 4.40 vs. 16.00 in healthy limbs in all patients. This difference was statistically significant (p<0.001). There was also a significantly (p<0.001) greater range of knee hyperextension on the side of injury (5.00 vs. 1.90 in healthy limbs). CONCLUSIONS: 1. Post-traumatic restriction of ankle dorsiflexion can cause knee joint overload. 2. Examinations of knee function during walking should be carried out in patients with trauma-related dysfunctions of the ankle joint in order to prevent secondary musculoskeletal abnormalities.


Asunto(s)
Fracturas de Tobillo/complicaciones , Fracturas de Tobillo/fisiopatología , Marcha , Articulación de la Rodilla/fisiopatología , Anomalías Musculoesqueléticas/prevención & control , Rango del Movimiento Articular , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Marcha/fisiología , Humanos , Masculino , Persona de Mediana Edad , Anomalías Musculoesqueléticas/etiología , Proyectos Piloto , Polonia , Recuperación de la Función
4.
Sci Rep ; 2: 679, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22997553

RESUMEN

Thalidomide, a sedative drug given to pregnant women, unfortunately caused limb deformities in thousands of babies. Recently the drug was revived because of its therapeutic potential; however the search is still ongoing for an antidote against thalidomide induced limb deformities. In the current study we found that nitric oxide (NO) rescues thalidomide affected chick (Gallus gallus) and zebrafish (Danio rerio) embryos. This study confirms that NO reduced the number of thalidomide mediated limb deformities by 94% and 80% in chick and zebrafish embryos respectively. NO prevents limb deformities by promoting angiogenesis, reducing oxidative stress and inactivating caspase-3 dependent apoptosis. We conclude that NO secures angiogenesis in the thalidomide treated embryos to protect them from deformities.


Asunto(s)
Inductores de la Angiogénesis/farmacología , Anomalías Musculoesqueléticas/inducido químicamente , Donantes de Óxido Nítrico/farmacología , Espermina/análogos & derivados , Teratógenos/toxicidad , Talidomida/toxicidad , Inductores de la Angiogénesis/uso terapéutico , Animales , Aorta/efectos de los fármacos , Aorta/patología , Apoptosis/efectos de los fármacos , Caspasa 3/metabolismo , Catalasa/fisiología , Embrión de Pollo , Evaluación Preclínica de Medicamentos , Desarrollo Embrionario/efectos de los fármacos , Células Endoteliales/efectos de los fármacos , Células Endoteliales/fisiología , Femenino , Técnicas In Vitro , Masculino , Anomalías Musculoesqueléticas/prevención & control , Neovascularización Fisiológica/efectos de los fármacos , Donantes de Óxido Nítrico/uso terapéutico , Óxido Nítrico Sintasa de Tipo III/biosíntesis , Especies Reactivas de Oxígeno/metabolismo , Espermina/farmacología , Espermina/uso terapéutico , Pez Cebra , Proteínas de Pez Cebra/metabolismo
5.
Genet Med ; 8(5): 318-27, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16702883

RESUMEN

Pompe disease (Glycogen storage disease type II, GSDII, or acid maltase deficiency) is an autosomal recessive disorder characterized by deficiency of acid alpha-glucosidase resulting in intra-lysosomal accumulation of glycogen and leading to progressive muscle dysfunction. The natural history of infantile-onset Pompe disease is characterized by hypertrophic cardiomyopathy and profound generalized weakness presenting in the first few months of life, with rapid progression and death usually occurring by one year of age. Late-onset Pompe disease is characterized by onset of symptoms after one year of age, less severe or absence of cardiac involvement and slower progression, with symptoms primarily related to progressive dysfunction of skeletal muscles and respiratory muscle involvement. Recent clinical trials of enzyme replacement therapy have begun to allow greater opportunity for potential improvement in motor status, function, and survival than ever before, with hopes of moving toward maximizing physical function for individuals with Pompe disease. Children are living longer with some achieving independent sitting, creeping, and walking-milestones typically never achieved in the untreated natural history of the disorder. With increased survival, clinical management based on an understanding of the pathology and pathokinesiology of motor function gains importance. This article reviews current knowledge regarding the motor system in Pompe disease and provides an overview of physical therapy management of Pompe disease, including management strategies for individuals on enzyme replacement therapy.


Asunto(s)
Enfermedad del Almacenamiento de Glucógeno Tipo II/terapia , Modalidades de Fisioterapia , Enfermedad del Almacenamiento de Glucógeno Tipo II/fisiopatología , Humanos , Lactante , Debilidad Muscular/fisiopatología , Debilidad Muscular/terapia , Músculo Esquelético/fisiopatología , Anomalías Musculoesqueléticas/prevención & control , Anomalías Musculoesqueléticas/terapia , Modalidades de Fisioterapia/normas
7.
Nihon Igaku Hoshasen Gakkai Zasshi ; 60(14): 845-55, 2000 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-11197835

RESUMEN

ICR mice fetuses in the organogenesis stage were used to clarify experimentally the mechanism of the protective effect of vitamin E derivant (TMG: 2-(alpha-D-Glucopyranosyl) methyl-2, -5, -7, -8-Teramethylchorman-6-working woman) on the effects of radiation. The authors paid careful attention to radiation, and the radioprotective effects of TMG on the induction of malformations was examined. Radiation is an important consideration because of its widespread use in the areas of medicine, nuclear energy, and industry. Malformations induced by radiation at the organogenesis stage, skeletal malformations, and the effects at the cellular level of embryos were examined in this research. Further, the mechanism of the protection effect of TMG against radiation-induced malformations was analyzed and observed experimentally. Thus, this study was done to provide fundamental data on the radioprotective agent TMG. It was clear that TMG exerted radioprotective effects against embryonic death and the rate of teratogenesis when administered before exposure. Such effects were also exerted against skeletal malformations and fetal body weight. In summary, radioprotective effects were observed at the whole-body level as well as at the cellular level.


Asunto(s)
Anomalías Inducidas por Radiación/prevención & control , Cromanos/farmacología , Depuradores de Radicales Libres/farmacología , Glicósidos/farmacología , Protectores contra Radiación/farmacología , Anomalías Inducidas por Radiación/embriología , Animales , Apoptosis/efectos de los fármacos , Apoptosis/efectos de la radiación , Blastocisto/efectos de los fármacos , Blastocisto/efectos de la radiación , Cromanos/uso terapéutico , Femenino , Muerte Fetal/prevención & control , Depuradores de Radicales Libres/uso terapéutico , Células Germinativas/citología , Glicósidos/uso terapéutico , Masculino , Ratones , Ratones Endogámicos ICR , Morfogénesis/efectos de los fármacos , Morfogénesis/efectos de la radiación , Anomalías Musculoesqueléticas/embriología , Anomalías Musculoesqueléticas/prevención & control , Embarazo , Dosis de Radiación , Protectores contra Radiación/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...